These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23119090)

  • 41. Pertussis seroimmunity among mother-infant pairs and infant immune response to pertussis vaccination.
    Saffar MJ; Ajami A; Khalilian AR; Qaheri A; Saffar H
    Indian Pediatr; 2007 Dec; 44(12):916-8. PubMed ID: 18175845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.
    Hallander HO; Andersson M; Gustafsson L; Ljungman M; Netterlid E
    APMIS; 2009 Dec; 117(12):912-22. PubMed ID: 20078557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study.
    Zhang Q; Zheng H; Liu M; Han K; Shu J; Wu C; Xu N; He Q; Luo H
    BMC Infect Dis; 2012 Jun; 12():138. PubMed ID: 22892100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
    Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
    Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.
    Caboré RN; Maertens K; Dobly A; Leuridan E; Van Damme P; Huygen K
    Virulence; 2017 Oct; 8(7):1245-1254. PubMed ID: 28277900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
    Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
    J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of anti-pertussis toxin ELISA and agglutination assays to assess immune responses to pertussis.
    Khramtsov P; Bochkova M; Timganova V; Zamorina S; Rayev M
    Infect Dis (Lond); 2017 Aug; 49(8):594-600. PubMed ID: 28335677
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A General Lack of IgG Against Pertussis Toxin in Chinese Pregnant Women and Newborns.
    Meng QH; Luo J; Yang F; Shen YJ; Li L; Li LJ; Shi W; Wang YJ; Yao KH
    Pediatr Infect Dis J; 2018 Sep; 37(9):934-938. PubMed ID: 29406469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay.
    Fry NK; Litt DJ; Duncan J; Vaghji L; Warrener L; Samuel D; Andrews N; Harnden A; Harrison TG
    J Med Microbiol; 2013 Sep; 62(Pt 9):1281-1289. PubMed ID: 23722435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
    Afari EA; Kamiya Y; Nkrumah FK; Dunyo SK; Akpedonu P; Kamiya H; Fukai F
    Ann Trop Paediatr; 1996 Mar; 16(1):39-48. PubMed ID: 8787364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Seroprevalence of Bordetella pertussis specific Immunoglobulin G antibody levels among asymptomatic individuals aged 4 to 24 years: a descriptive cross sectional study from Sri Lanka.
    Sigera S; Perera J; Rasarathinam J; Samaranayake D; Ediriweera D
    BMC Infect Dis; 2016 Dec; 16(1):729. PubMed ID: 27905894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Serum immunoglobulin IgG subclass distribution of antibody responses to pertussis toxin and filamentous hemagglutinin of Bordetella pertussis in patients with whooping cough].
    Rastawicki W; Smietańska K; Rokosz-Chudziak N; Jagielski M
    Med Dosw Mikrobiol; 2013; 65(4):269-74. PubMed ID: 24730215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pertussis seroprevalence in korean adolescents and adults using anti-pertussis toxin immunoglobulin G.
    Lee SY; Han SB; Bae EY; Kim JH; Kang JH; Park YJ; Ma SH
    J Korean Med Sci; 2014 May; 29(5):652-6. PubMed ID: 24851020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune responses to Bordetella pertussis infection and vaccination.
    Tomoda T; Ogura H; Kurashige T
    J Infect Dis; 1991 Mar; 163(3):559-63. PubMed ID: 1995729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
    Patel SS; Wagstaff AJ
    Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study.
    Torzsa P; Devadiga R; Tafalla M
    BMC Infect Dis; 2017 Apr; 17(1):242. PubMed ID: 28376739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.